MARKET

APTX

APTX

Aptinyx
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.140
+0.030
+0.96%
Closed 16:00 09/25 EDT
OPEN
3.110
PREV CLOSE
3.110
HIGH
3.310
LOW
3.050
VOLUME
118.18K
TURNOVER
--
52 WEEK HIGH
5.28
52 WEEK LOW
1.600
MARKET CAP
147.46M
P/E (TTM)
-2.1535
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Aptinyx to Present at Upcoming Virtual Investor Conferences
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will be presenting at the following virtual investor conferences:
Business Wire · 09/03 12:37
Is Aptinyx (NASDAQ:APTX) In A Good Position To Deliver On Growth Plans?
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Simply Wall St. · 08/21 14:33
Aptinyx (APTX) Investor Presentation - Slideshow
The following slide deck was published by Aptinyx Inc. in conjunction with this event.
Seekingalpha · 08/16 20:15
Aptinyx Q2 EPS $(0.27) Beats $(0.28) Estimate, Sales $490.00K Down From $925.00K YoY
Aptinyx (NASDAQ:APTX) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.28) by 3.57 percent. This is a 25 percent increase over losses of $(0.36) per share from the same
Benzinga · 08/13 20:11
Aptinyx EPS beats by $0.01, misses on revenue
Aptinyx (APTX): Q2 GAAP EPS of -$0.27 beats by $0.01.Revenue of $0.49M (-47.3% Y/Y) misses by $0.37M.Press Release
Seekingalpha · 08/13 20:08
The Daily Biotech Pulse: Mesoblast Awaits Adcom Test, BioCryst Rallies On Insider Buying, Sorrento Hits Back At Short Seller
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12)
Benzinga · 08/13 12:18
Aptinyx Inc. (APTX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Aptinyx Inc. (APTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 08/06 16:30
Aptinyx to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will be presenting at the 2020 Wedbush PacGrow Healthca
Business Wire · 08/04 12:37
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of APTX. Analyze the recent business situations of Aptinyx through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average APTX stock price target is 10.67 with a high estimate of 15.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 96
Institutional Holdings: 27.95M
% Owned: 59.52%
Shares Outstanding: 46.96M
TypeInstitutionsShares
Increased
24
3.17M
New
36
-887.77K
Decreased
9
310.67K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.88%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
Chairman/Independent Director
Patrick Enright
President/Chief Executive Officer/Director
Norbert Riedel
Chief Financial Officer
Ashish Khanna
Chief Operating Officer
Andrew Kidd
Independent Director
Henry Gosebruch
Independent Director
Elisha Gould
Independent Director
Robert Hombach
Independent Director
Adam Koppel
Independent Director
Rachel Sherman
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About APTX
Aptinyx Inc. is a clinical-stage biopharmaceutical company. The Company discovers and develops therapies for disorders of the brain and nervous system. The Company has a platform for discovering compounds that work through a mechanism, which includes modulation of the N-methyl-D-aspartate (NMDA) receptor to develop pathways involved with nerve cell communication. The Company's compounds are effective on disease models including, depression, neuropathic pain, migraine, traumatic brain injury and age-induced learning impairment. The Company's compounds facilitate receptor activation without over-activating the receptor. The Company’s lead product candidate is NYX-2925, a treatment for the painful diabetic peripheral neuropathy. It is also developing NYX-783 for the treatment of post-traumatic stress disorder and NYX-458 for Parkinson’s disease cognitive impairment. The Company in partnership with Allergan plc, develops AGN-241751 for major depressive disorder indications.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Aptinyx Inc stock information, including NASDAQ:APTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading APTX stock methods without spending real money on the virtual paper trading platform.